Sign in
Taking peoplePhase 3

A Study to Evaluate the Efficacy and Safety of BRC-201 in Patients With Acute Uncomplicated Influenza

Key facts

Who runs it
Boryung Biopharma Co., Ltd.
Where
South Korea1 site in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
Phase
Phase 3
People taking part
348 people, planned
Started
Nov 2026
Expected to end
Apr 2027
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • BRC-201
  • Placebo
Record updated
17 November 2026

Who can take part

Age
12 years to 64 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 13 criteriaShow less

Who can take part

  • Male or female participants aged 12 to less than 65 years who provide written informed consent or assent, as applicable
  • Laboratory-confirmed influenza A and/or B infection by RIDT or PCR, with an axillary temperature ≥38.0°C and at least one systemic and one respiratory symptom of moderate or greater severity (score ≥2)
  • Onset of influenza-related symptoms within 48 hours before randomization
  • Willing and able to comply with the protocol-specified contraception requirements
  • Able to comply with study procedures, scheduled visits, and symptom diary completion

Who cannot take part

  • Suspected or confirmed lower respiratory tract disease on chest X-ray, recent acute respiratory infection, or concomitant infection requiring systemic antimicrobial treatment
  • History of dysphagia, gastrointestinal conditions affecting drug absorption, or hypersensitivity to the investigational product, acetaminophen, or NSAIDs
  • Use of anti-influenza medication within 7 days, or another investigational drug or device treatment within 30 days before randomization
  • Severe or critical influenza infection requiring hospitalization or intensive care
  • Significant uncontrolled underlying diseases or conditions associated with an increased risk of severe influenza, including immunodeficiency and clinically significant hepatic, renal, cardiovascular, or respiratory diseases
  • BMI >30.0 kg/m², body weight <40.0 kg, or positive COVID-19 test at screening
  • Any other condition that, in the investigator's opinion, makes the participant unsuitable for the study
  • Clinically significant infection-related findings, including leukocyte count >10.0 × 10⁹/L, purulent sputum, or purulent tonsillitis

The main criteria, as questions

These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Are you between 12 and 64 years old?

This trial is currently available in South Korea.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This is a Phase 3, multicenter, randomized, double-blind clinical study designed to evaluate the efficacy and safety of BRC-201 in adult and adolescent patients with acute uncomplicated influenza virus infection.

Read full original descriptionShow less

The study aims to assess the efficacy of BRC-201 in treating influenza symptoms and to evaluate its safety in patients with influenza.

The 2 groups in the trial

  • BRC-201Treatment being tested

    Participants will receive a single oral dose of BRC-201 (40 mg for participants weighing less than 80 kg or 80 mg for those weighing 80 kg or more).

  • PlaceboPlacebo, for comparison

    Participants will receive a single oral dose of placebo matching BRC-201 (2 capsules for participants weighing less than 80 kg or 4 capsules for those weighing 80 kg or more).

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy and Safety of BRC-201 in Adult and Adolescent Patients With Acute Uncomplicated Influenza Virus Infection
Criteria questions
Built from NCT07943390, who can take part
Record updated
17 November 2026